About the Company

Biophytis (Euronext Paris: ALBPS.PA) is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for age-related diseases. The Company has two clinical-stage product candidates in development: Sarcob (BIO101) and Maculia (BIO201). Sarcob is a small molecule for the treatment of sarcopenic obesity designed to slow muscle atrophy. Initial signs of clinical activity were demonstrated in a Phase I/II study in healthy, obese volunteers. The Company is preparing to initiate a randomized Phase IIb trial for Sarcob in the second half of 2016. The Company’s second product candidate is Maculia, a PPAR agonist for the treatment of dry age-related macular degeneration (AMD). Preclinical data indicate that Maculia may reduce oxidative stress in cells of the retina. Biophytis is preparing to initiate a Phase IIb study for Maculia in the second half of 2016.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research